Literature DB >> 19380765

CD59 blockade enhances antigen-specific CD4+ T cell responses in humans: a new target for cancer immunotherapy?

Baalasubramanian Sivasankar1, M Paula Longhi, Kathleen M E Gallagher, Gareth J Betts, B Paul Morgan, Andrew J Godkin, Awen M Gallimore.   

Abstract

CD59, a broadly expressed GPI-anchored molecule, regulates formation of the membrane attack complex of the complement cascade. We previously demonstrated that mouse CD59 also down-modulates CD4(+) T cell activity in vivo. In this study, we explored the role of CD59 on human CD4(+) T cells. Our data demonstrate that CD59 is up-regulated on activated CD4(+) T cells and serves to down-modulate their activity in response to polyclonal and Ag-specific stimulation. The therapeutic potential of this finding was explored using T cells isolated from colorectal cancer patients. The findings were striking and indicated that blockade of CD59 significantly enhanced the CD4(+) T cell response to two different tumor Ags. These data highlight the potential for manipulating CD59 expression on T cells for boosting weak immune responses, such as those found in individuals with cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19380765      PMCID: PMC2704398          DOI: 10.4049/jimmunol.0804243

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  13 in total

1.  Expression of the DAF (CD55) and CD59 antigens during normal hematopoietic cell differentiation.

Authors:  L W Terstappen; M Nguyen; H M Lazarus; M E Medof
Journal:  J Leukoc Biol       Date:  1992-12       Impact factor: 4.962

2.  CD59 functions as a signal-transducing molecule for human T cell activation.

Authors:  P E Korty; C Brando; E M Shevach
Journal:  J Immunol       Date:  1991-06-15       Impact factor: 5.422

3.  Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1.

Authors:  Naomi N Hunder; Herschel Wallen; Jianhong Cao; Deborah W Hendricks; John Z Reilly; Rebecca Rodmyre; Achim Jungbluth; Sacha Gnjatic; John A Thompson; Cassian Yee
Journal:  N Engl J Med       Date:  2008-06-19       Impact factor: 91.245

4.  Cutting edge: murine CD59a modulates antiviral CD4+ T cell activity in a complement-independent manner.

Authors:  M Paula Longhi; Baalasubramanian Sivasankar; Nader Omidvar; B Paul Morgan; Awen Gallimore
Journal:  J Immunol       Date:  2005-12-01       Impact factor: 5.422

5.  Characterization of the murine 5T4 oncofoetal antigen: a target for immunotherapy in cancer.

Authors:  Andrew M Woods; Who W Wang; David M Shaw; Christopher M Ward; Miles W Carroll; Buddug R Rees; Peter L Stern
Journal:  Biochem J       Date:  2002-08-15       Impact factor: 3.857

Review 6.  Alternative roles for CD59.

Authors:  Fiona C Kimberley; Baalasubramanian Sivasankar; B Paul Morgan
Journal:  Mol Immunol       Date:  2006-08-01       Impact factor: 4.407

7.  CD59a is the primary regulator of membrane attack complex assembly in the mouse.

Authors:  Sivasankar Baalasubramanian; Claire L Harris; Rossen M Donev; Masashi Mizuno; Nader Omidvar; Wen-Chao Song; B Paul Morgan
Journal:  J Immunol       Date:  2004-09-15       Impact factor: 5.422

Review 8.  Carcinoembryonic antigen gene family: molecular biology and clinical perspectives.

Authors:  J A Thompson; F Grunert; W Zimmermann
Journal:  J Clin Lab Anal       Date:  1991       Impact factor: 2.352

9.  CD4+CD25+FOXP3+ regulatory T cells suppress anti-tumor immune responses in patients with colorectal cancer.

Authors:  Sarah L Clarke; Gareth J Betts; Andrea Plant; Kate L Wright; Tariq M El-Shanawany; Richard Harrop; Jared Torkington; Brian I Rees; Geraint T Williams; Awen M Gallimore; Andrew J Godkin
Journal:  PLoS One       Date:  2006-12-27       Impact factor: 3.240

10.  Direct expansion of functional CD25+ CD4+ regulatory T cells by antigen-processing dendritic cells.

Authors:  Sayuri Yamazaki; Tomonori Iyoda; Kristin Tarbell; Kara Olson; Klara Velinzon; Kayo Inaba; Ralph M Steinman
Journal:  J Exp Med       Date:  2003-07-21       Impact factor: 14.307

View more
  18 in total

Review 1.  Protein engineering to target complement evasion in cancer.

Authors:  Darrick Carter; André Lieber
Journal:  FEBS Lett       Date:  2013-11-14       Impact factor: 4.124

Review 2.  Complement regulators and inhibitory proteins.

Authors:  Peter F Zipfel; Christine Skerka
Journal:  Nat Rev Immunol       Date:  2009-09-04       Impact factor: 53.106

3.  Association of CD59 and CFH polymorphisms with acute anterior uveitis in Chinese population.

Authors:  Q F Wang; X F Huang; Z L Zheng; M L Dai; W J Cai; M M Yang; Z B Jin; Y Q Wang
Journal:  Eye (Lond)       Date:  2016-07-15       Impact factor: 3.775

4.  Impact of Genetic Polymorphisms on Human Immune Cell Gene Expression.

Authors:  Benjamin J Schmiedel; Divya Singh; Ariel Madrigal; Alan G Valdovino-Gonzalez; Brandie M White; Jose Zapardiel-Gonzalo; Brendan Ha; Gokmen Altay; Jason A Greenbaum; Graham McVicker; Grégory Seumois; Anjana Rao; Mitchell Kronenberg; Bjoern Peters; Pandurangan Vijayanand
Journal:  Cell       Date:  2018-11-15       Impact factor: 41.582

5.  Generation of 1E8 Single Chain Fv-Fc Construct Against Human CD59.

Authors:  Jeong-Won Hong; Woon-Dong Cho; Kwon Pyo Hong; So-Seul Kim; Seung-Myoung Son; Seok-Joong Yun; Ho-Chang Lee; Sang-Soon Yoon; Hyung-Geun Song
Journal:  Immune Netw       Date:  2012-02-29       Impact factor: 6.303

6.  Lck mediates signal transmission from CD59 to the TCR/CD3 pathway in Jurkat T cells.

Authors:  Anna M Lipp; Kata Juhasz; Christian Paar; Christoph Ogris; Paul Eckerstorfer; Roland Thuenauer; Jan Hesse; Benedikt Nimmervoll; Hannes Stockinger; Gerhard J Schütz; Ulrich Bodenhofer; Zsolt Balogi; Alois Sonnleitner
Journal:  PLoS One       Date:  2014-01-15       Impact factor: 3.240

7.  Highly skewed distribution of miRNAs and proteins between colorectal cancer cells and their exosomes following Cetuximab treatment: biomolecular, genetic and translational implications.

Authors:  Marco Ragusa; Luisa Statello; Marco Maugeri; Cristina Barbagallo; Roberta Passanisi; Mohamed S Alhamdani; Giovanni Li Destri; Alessandro Cappellani; Davide Barbagallo; Marina Scalia; Hadi Valadi; Jörg D Hoheisel; Cinzia Di Pietro; Michele Purrello
Journal:  Oncoscience       Date:  2014-03-16

Review 8.  Complement as a regulator of adaptive immunity.

Authors:  Justin Killick; Gregoire Morisse; Dirk Sieger; Anne L Astier
Journal:  Semin Immunopathol       Date:  2017-08-25       Impact factor: 9.623

9.  The Targeted Antitumor Effects of C- PC/CMC-CD59sp Nanoparticles on HeLa Cells in Vitro and in Vivo.

Authors:  Yujuan Wang; Liangqian Jiang; Qifeng Yin; Huihui Liu; Guoxiang Liu; Guoteng Zhu; Bing Li
Journal:  J Cancer       Date:  2017-08-25       Impact factor: 4.207

10.  Screening preeclamptic cord plasma for proteins associated with decreased breast cancer susceptibility.

Authors:  Hoi Pang Low; Ashutosh Tiwari; Jagadeesh Janjanam; Li Qiu; Chien-I Chang; William C Strohsnitter; Errol R Norwitz; Sun W Tam; James E Evans; Karin M Green; Joao A Paulo; Mats Lambe; Chung-Cheng Hsieh
Journal:  Genomics Proteomics Bioinformatics       Date:  2013-12-05       Impact factor: 7.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.